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Abstract.  The growth of A-1  fibroblasts depends on 
exogenous amyloid ~/A4 protein precursor (APP), 
providing a  simple bioassay to study the function of 
APP. Our preliminary  study, testing the activity of a 
series of fragments derived from the secreted form of 
APP-695 (sAPP-695) on this bioassay, has shown that 
at least one of the active sites of sAPP-695 was local- 
ized within a 40-mer sequence (APP296-335, Kang se- 
quence; Roch, J.-M.,  I. P. Shapiro,  M.  P.  Sundsmo, 
D.  A.  C.  Otero, L.  M.  Refolo, N.  K.  Robakis, and 
T.  Saitoh.  1992. Z  BioL  Chem.  267:2214-2221).  In 
the present study, to further characterize the growth- 
promoting activity of sAPP-695 on fibroblasts, we ap- 
plied a battery of synthetic peptides on this bioassay 
and found that:  (a) the sequence of five amino acids, 
RERMS (APP328-332),  was uniquely required for the 
growth-promoting activity of sAPP-695; (b) the activ- 
ity was sequence-specific because the reverse-sequence 
peptide of the active domain had no activity; and (c) 
the four-amino-acid peptide RMSQ (APP330-333), 
which partially overlaps the COOH-terminal side of 
the active sequence RERMS, could antagonize the ac- 
tivity of sAPP-695.  Furthermore,  a recombinant pro- 
tein which lacks this active domain (APP20-591  with- 
out 306-335) did not promote fibroblast cell growth, 
suggesting that this domain is the only site of sAPP- 
695 involved in the growth stimulation.  The availabil- 
ity of these biologically active,  short peptides and 
their antagonists  should prove to be an essential step 
for the elucidation of APP involvement in regulation 
of cellular homeostasis. 
T 
rI~ amyloid/~/A4 protein is the major component of 
cerebrovascular  amyloid deposits (Glenner and Wong, 
1984) and the core of neuritic plaques (Masters et al., 
1985; Selkoe et al., 1986), the latter of which is believed to 
be the hallmark  of the pathology found in brain tissue of pa- 
tients afflicted with Alzheimer's  disease (AD). l The protein 
is derived from a membrane-spanning  protein,  amyloid 8/ 
A4 protein precursor (APP) (Robakis et al.,  1987; Kang et 
al.,  1987; Goldgaber et al.,  1987; Tanzi et al.,  1987),  of 
which  at  least five different  forms of primary  translation 
products are now known.  Three forms (APP-563, -751, and 
-770) contain a domain showing a strong homology with pro- 
tease inhibitors  of the Kunitz type (KPI) whereas the other 
two forms (APP-695 and -714) do not (Kitaguchi et al., 1988; 
Ponte et al.,  1988; Tanzi et al.,  1988; De Sauvage and Oc- 
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1. Abbreviations  used in this paper: AD, Alzheimer's disease; APE amyloid 
precursor protein; CM, conditioned medium; KPI, Kunitz-type protease in- 
hibitor; OPC, oligonucleotide  purification  cartridge;  sAPP, secreted forms 
of APP; TPBS,  PBS containing 0.1% Tween 20, 
tave,  1989;  Golde et al.,  1990).  Subsequent studies  have 
shown the existence of secreted forms of APP (sAPP), either 
in the medium of cultured cells, such as PC12 and fibroblasts 
(Schubert  et al.,  1989a;  U6da et al.,  1989; Weidemann  et 
al., 1989), or in the cerebrospinal fluid (Palmert et al., 1989; 
Weidemann et al.,  1989; Kitaguchi  et al.,  1990). Since the 
identification  of KPI-containing  forms of sAPP as protease 
nexin II (Oltersdorf et al., 1989; Van Nostrand et al., 1989), 
many reports have appeared describing  biological functions 
for these forms of sAPP. These include roles in the regulation 
of neurite  extension  (Oltersdorf et al.,  1989; Van Nostrand 
et al.,  1989),  the blood coagulation  process (Cole et al., 
1990; Smith et al.,  1990; Van Nostrand et al.,  1990),  and 
the wound-healing process (Cunningham and Van Nostrand, 
1991). Little is known, however, about the physiological func- 
tion of sAPP-695 which lacks the KPI domain, in spite of the 
evidence indicating that APP-695 is the major form of APP 
mRNA in the brain (Neve et al.,  1988; Ponte et al.,  1988; 
Tanaka et al., 1988; K6nig et al., 1991). Curiously, however, 
at the protein level, it has been reported that APP-695 repre- 
sents only a minor fraction of total brain APP (Van Nostrand 
et al., 1991). Nevertheless,  the fact remains that APP-695 is 
found almost exclusively in brain tissue and i~ activity could 
underlie a brain-specific  mechanism. 
As an initial  attempt  to study physiological  functions  of 
APE we established  a fibroblast  cell line,  A-l,  transfected 
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al., 1989). This cell line produces very low levels of APP 
mRNA  and  its  translation  products,  resulting  in  a  slow 
growth rate. The growth of A-1 cells can be restored to the 
level of  normal (parent) fibroblasts (AG2804) by the addition 
of exogenous APP, either APP-695 or APP-751/770, into the 
culture medium (Saitoh et al.,  1989; Bhasin et al.,  1991). 
Although the biochemical basis for the retarded growth rate 
of A-1 cells is still unclear, the dependence of the growth of 
cells on exogenous APP provided us with a rather  simple 
bioassay for the functional mapping of APP (Roch et al., 
1992). Testing the activity of  a series of sAPP-695 fragments 
obtained from our bacterial expression system on this bioas- 
say, we have already shown that at least one of the sites of 
sAPP-695 responsible for the growth stimulation is located 
within a 40-mer  sequence  (APP296-335, Kang sequence) 
(Roch et al.,  1992). 
In the present study, to further characterize the growth- 
promoting activity of  sAPP-695 on fibroblasts, we addressed 
the following questions:  (a)  Which  amino  acid  sequence 
within the 40-mer domain is essential for the activity? (b) Is 
the activity sequence-specific? (c) Does the 40-mer domain 
contain the only site of sAPP-695 capable of growth stimu- 
lation? 
We found that the sequence of five amino acids, RERMS 
(APP328-332),  was  uniquely  required  for  the  growth- 
promoting  activity  of sAPP-695 on  fibroblasts.  We  also 
found that the  four-amino-acid peptide  RMSQ  (APP330- 
333), which partially overlaps the COOH-terminal  side of 
the active sequence RERMS, could antagonize the activity 
of sAPP-695. These  findings firmly establish  the growth- 
stimulating activity of sAPP-695 which lacks the KPI do- 
main.  The  availability  of these  agonists  and  antagonists 
should be useful in further delineating the biological activity 
of sAPP-695 in physiological and pathological conditions. 
Materials and Methods 
Cell Culture 
A-I  and  AG2804  fibroblasts were  maintained  as  described previously 
(Saitoh et al., 1989). In brief, AG2804 cells were cultured in DME contain- 
ing 10% FCS in 75-cm  2 flasks, at 37°C in 8% C(h, with one passage per 
week. A-1 cells were maintained in the same way with the exception that 
the media contained the conditioned media (CM) from AG2804 cell culture 
(20% vol/vol). Inclusion of the CM from AG2804 ceils was necessary be- 
cause the growth of A1 cells was significantly slower than that of AG2804 
cells and was restored by the addition of  the CM (Saitoh et al., 1989; Bhasin 
et al., 1991). To eliminate any residual effect of the CM, A1 cells used for 
the growth assay were kept in regular media (DME/10% FCS) without CM 
for 1 wk before the assay. 
Growth Assays 
Cells at 70-80% confiuency were detached from the substratum by incubat- 
ing in PBS containing 1 mM EDTA. The detached cells were harvested, 
centrifuged, and resuspended in  DME/10%  FCS at  a  density of 5,000 
ceUs/ml. The cell suspension was then seeded in six-well plates (2 ml/well) 
and the plates were kept at 37oc in a CO2 incubator for 1 h. The relevant 
peptide solution in DME (100  ~1) was then added. The same volume of 
DME without peptide was added in control wells. The plates were kept at 
37°C in a CO2 incubator for 3 d and the cell number in each well was de- 
termined using a Coulter cell counter, model ZF (Coulter Electronics Inc., 
Hialeah, FL). The results were expressed as the percentage increase in the 
cell number compared to the number of the cells seeded. All the growth 
assays were done in triplicate. For the measurement of [3H]thymidine in- 
corporation, the cells were washed after a 3-d incubation with DME and 
then incubated in DME containing [3H]thymidine (5 #Ci/ml,  1 nil/well 
Amersham Corp., Arlington Heights, IL) for 3 h at 37°C in a CO2 incuba- 
tor. The cells were then fixed with 100%  methanol/glacial acetic acid (1:3 
vol/vol) and washed with ice-cold 10% TCA (0.5 ml x  5 times). The radio- 
activity remaining in the cells was extract~l by overnight incubation in 0.5 
ml of 1 N NaOH and was counted in 10 ml of scintillation cocktail. 
Preparation of  Synthetic Peptides 
A battery of peptides corresponding to all or part of APP296-335 (Table 
I) were synthesized using a Rainin PS3 peptide synthesizer and purified on 
a C-18 reverse-phase HPLC column. Each peptide was recovered in 40% 
acetonitrile. This solvent was eliminated by evaporation under vacuum, and 
the peptide was resolubilized in 50 mM NaI-ICO3 (pH 7.4).  Because both 
C6 and C7 peptides were insoluble in the buffer due to their hydrophobicity, 
they were first dissolved in DMSO and then diluted to give a final concentra- 
tion of DMSO <0.01%  in the assay media. The presence of 0.01% DMSO 
in the media did not affect the growth of AA cells (data not shown). All of 
the other peptides used were soluble in the sodium bicarbonate buffer. 
Plasmid Construction and Bacterial Expression 
of  KB75 (APP20-591, Kang Sequence) and KB758 
(APP20-591 without 306-335) 
The construction of pKB75, encoding the amino acids Val-20 to Ile-591  of 
APP-695, has been described (Roch et al., 1992). The strategy for the con- 
struction of the plasmid pKB75~ is shown in Fig. 4 A. The oligonucleotides 
used as primers in the PCR were synthesized in a PCR-mate DNA syn- 
thesizer (Applied Biosystems, Inc., Foster City, CA) and purified by the 
oligonucleotide purification cartridge (OPC) system provided by the same 
supplier.  The sequence of the 5' primer was 5'-GACAGTGTCACTCGA- 
GAGAGAATGGGAAGA~GAA-3' and the 3' primer was 5'-GGACTG- 
AGTCCTCGAGCTAGATCTCCTCCGTCTTGATATT-Y.  The template for 
the PCR reaction was the 2.4-kb SmaI-Xmnl fragment of APP-695 eDNA. 
The reaction was carried out in 100 #1 PCR buffer containing 500 ng of 
template DNA,  1 #M of each primer, 200/~M of each dNTE and 1.5 U 
of  the enzyme AmpliTaq. The sample was brought to a temperature of 94°C 
for 3 min, followed by 38 cycles of the following sequence: 940C for 30 s, 
550C for 1 re_in, and 72°C for 1 rain. After the last cycle, a final extension 
step was performed at 72°C for 7 rain. The PCR product (800 bp in length) 
was finally purified by electrophoresis in  1%  agarose gel, binding to a 
DEAE-cellulose membrane, elution in  1 M  NaC1 at 65°C,  and ethanol 
precipitation. The purified PCR product was then digested with XhoI re- 
striction enzyme and ligated into the plasmid pKW/5 previously digested 
with XhoI and treated with canine intestine alkaline phosphatase. Compe- 
tent Escherichia coil MCI061 cells were transformed with the ligation mix- 
tures and clones were selected for ampicillin resistance. The size and orien- 
tation of the insert were determined by restriction analysis, using different 
enzymes having asymmetrical restriction sites. Positive clones were tested 
for expression of APP-derived peptides of appropriate size by immunoblot- 
ring with an anti-APP antibody (anti-GID) as described below. The new 
plasmid was named pKff758. 
Immunoblotting 
We used anti-GID antibody, a rabbit polyclonal antibody against the peptide 
175-186 of APP (Saitoh et al., 1989; Cole et al., 1991), to verify the pro- 
teins expressed in bacteria. Proteins were separated by 8-16% PAGE in the 
presence of SDS (Laemmli,  1970)  and transferred onto a  nitrocellulose 
filter. After blocking the nonspecific binding site by incubation in PBS con- 
taining 0.1% Tween 20 (TPBS) for 1 h at room temperature, the filter was 
incubated overnight at 4°C in PBS containing 3% BSA and the antibody 
(1:2,000),  washed five times for 5 rain in TPBS at room temperature, in- 
cubated 2 h at 4°C in PBS containing 3% BSA and t25I-protein A (Amer- 
sham Co., 0.3/~Ci/ml), washed again as described above, and exposed onto 
Kodak RP film for 2 h at room temperature. 
Statistical Analysis 
Experimental group comparisons of mean cell numbers and [3H]thymidine 
incorporations were performed by analysis of  variance (ANOVA). The Dun- 
nett's multiple comparison test was subsequently used to assess possible 
differences between the control group and the experimental groups, at the 
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is indicated in each figure  legend. 
Results 
In the previous report (Roch et al.,  1992), we showed that 
both KB75  (APP20-591)  and a  40-mer peptide (APP296- 
335) were active on the A-1 cell growth assay. To find out the 
amino acid sequence within the 40-mer peptide which is es- 
sential for its activity, we synthesized a battery of peptides 
and tested their activity on the A-1  cell growth assay.  The 
amino  acid  sequences  of the  synthetic peptides  used  are 
given in Table I.  First,  three peptides which covered the 
NH2-terminal  (14-mer),  mid-  (13-mer),  and  COOH-ter- 
minal  (17-mer) portions of the 40-mer were tested.  Only 
the 17-mer was active (Fig. 1 A). Second, two peptides which 
covered the NH2-terminal (8-mer) and COOH-terminal (11- 
mer) portions of  the 17-mer were tested. Only the 11-mer was 
active (Fig.  1 B).  Third,  six peptides  which covered the 
NH2-terminal  (N4  and  N5),  mid-  (M5  and  M6),  and 
COOH-terminal (C6 and C7) portions of the  11-mer  were 
tested. The M5 and M6 peptides were active, although the 
concentrations required for significant effects were ,,ol0-fold 
higher than those of other active peptides described above 
(Fig. 1 C). Neither N4/N5 nor C6/C7 were active. The nega- 
tive results for C7 (ERMSQVM) and C6 (RMSQVM) sug- 
gested  that  the  NH2-terminal  R  and  E  residues  of M5 
(RERMS)  were  indispensable  for  the  activity.  To  see 
whether the COOH-terminal S and M residues are dispensa- 
ble or not, we tested M4 (RERM) and M3 (RER) and found 
no activity (Fig.  1 D), suggesting that both of the COOH- 
terminal residues were required for the activity. Thus, we 
have narrowed down the site responsible for the growth stim- 
ulation  of  fibroblasts  to  the  five-amino-acid  sequence 
RERMS  (APP328-332,  Kang  sequence).  To  test  the  se- 
quence  specificity of the  activity,  we  tested  the  reverse- 
sequence  17-mer and found no activity (Fig.  1 B).  As an 
additional parameter of cell growth, incorporation of [3H]- 
thymidine  into the cells  was  determined.  Three days ex- 
posure of cells to either KB75 or 17-mer (both at  10 pM) 
caused a  significant increase in the incorporation (Fig.  2) 
reflecting an increase in the cell number per well, whereas 
neither 14-mer nor 13-mer caused higher levels of [3H]thy- 
midine incorporation at the same concentrations, consistent 
with the results of cell numbers. 
One possible mechanism for the action of these APP pep- 
tides is the interaction of  APP with specific cell-surface mol- 
ecule(s).  The  sequence  specificity of the  activity,  as  de- 
scribed above, seemed to support this idea. If this is the case, 
it is expected that the inactive peptides which partially over- 
lap the active sequence RERMS might have an antagonistic 
action against the active peptides. According to this idea, we 
tested the activity of either 17-mer or KB75 (at 10 pM) in the 
presence of excess concentration (10 nM) of inactive pep- 
tides which partially overlaps RERMS,  and we found that 
both C7 and C6, but not N4, antagonized the activity of the 
peptides (Fig. 3). This antagonistic action was not an artifact 
caused  by  DMSO  because  C4  (RMSQ),  a  water-soluble 
derivative of C6, had a similar antagonistic action (Fig. 3). 
C4  by itself had  no growth-stimulating  activity (data not 
shown). 
The fact that the same peptide (C4) could antagonize the 
activities of either 17-mer or KB75 to a similar extent was 
indirect evidence that this domain (17-mer) represented the 
only active site of KB75.  To see more directly whether this 
domain is the only active site of sAPP-695 or whether there 
is an additional active site, we engineered a construct which 
encodes APP20-591  without 306-335  (pKB75~5) (Fig. 4 A 
and B). Recombinant protein KB75c5 was obtained through 
bacterial  expression and  protein  purification procedures, 
which were exactly the same as employed for the preparation 
of KB75 (Roch et al., 1992). Immunoblotting with anti-GID 
antibody detected the expression of KB'/56 in the partially 
purified bacterial lysate, with a predicted difference in the 
molecular weight from that of KB75 (Fig. 4 C). The peptide 
was further purified, through heparin-agarose column and 
Table L Amino Acid Sequences  of the Peptides Used in the Present Study* 
Peptide  Sequence 
KB75  APP20-591, K~g s~uence 
KB756  APP20-591 wi~out 306-335 
40-mer  TPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVM  (APP296-335) 
14-mer  TPDAVDKYLETPGD 
13-mer  GDENEHAHFQKAK 
17-mer  AKERLEAKHRERMSQVM 
Reversesequencel7-mer  MVQSMRERHKAELREKA 
8-mer  AKERLEAK 
11-mer  AKHRERMSQVM 
N5  AKHRE 
N4  KHRE 
M6  HRERMS 
M5  RERMS 
M4  RERM 
M3  RER 
C7  ERMSQVM 
C6  RMSQVM 
C4  RMSQ 
* KB75 and KB75~  were expressed  in our bacterial  expression  system. All the other  peptides were  chemically  synthesized.  See Materials and Methods for details. 
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activity  of APP peptides  on 
A-1 ceils. The growth assay on 
A-I cells was performed as de- 
scribed under Materials and 
Methods, using increasing con- 
centrations of APP peptides. 
The amino acid sequence  of 
each peptide is given in Table 
I.  In each  panel,  the  lower 
dotted line and the shaded area 
represent the mean ±  SEM of 
the percentage increase of A-I 
cell numbers after 3 d culture 
in the regular media (DME/ 
10%  FCS)  (basal  increase). 
As shown, the basal increase 
in the number of A-I cells was 
virtually zero. The upper dot- 
ted line and the shaded  area 
represent the mean ±  SEM of 
the  percentage  increase  of 
AG2804  cell  numbers  after 
3 d culture in the regular me- 
dia, which was determined in 
parallel in each  experiment. 
Each  point  represents  the 
mean ±  SEM of at least four 
determinations, each done in 
triplicate.  * p < 0.05, signifi- 
cantly different from the basal 
increase (differences were as- 
sessed by ANOVA  followed by 
the Durmett's test). 
Figure 2.  Effects of APP peptides on [3H]thymidine incorporation 
into A-I cells. After 3 d incubation  in the presence or absence (con- 
trol)  of the indicated peptide,  [3H]thymidine incorporation into 
the cell layer  was determined as described under Materials  and 
Methods. The concentration  of each peptide was 10 pM. Each bar 
represents the mean ±  SEM of three determinations, each done in 
triplicate.  * p < 0.05, significantly different from the control value 
(differences were assessed  by ANOVA followed by the Dunnett's 
test). 
Figure 3. Excess C6, C7, or C4, but not N4, antagonized the activity 
of 17-mer or KB75. The growth assay on A-1 cells was performed 
as described under Materials and Methods.  The active peptide in- 
cluded was 17-met (A) or KB75 (B), both at 10 pM, in the absence 
(white bars) or presence (gray bars) of the second peptide as indi- 
cated. The concentrations  of N4, C7, C6, and C4 were 10 nM. The 
amino acid sequence of each peptide is given in Table I. Each bar 
represents the percentage increase of the number of cells compared 
to the number of seeded cells (mean +  SEM of three determina- 
tions, each done in  triplicate.  * p < 0.05, significantly different from 
the values in the absence of the second peptide (differences were 
assessed by ANOVA followed by the Dunnett's test). 
The Journal of Cell Biology, Volume 121, 1993  882 Figure 4.  Deletion of the active domain of sAPP-695.  (A) The structure of pKB75  encoding APP20-591  was described in the previous 
report (Roch et al., 1992). Using the APP-695 eDNA as a template, we carried out PCR to produce a DNA fragment coding for the APP-695 
region extending from Arg-336 to I1e-591 (end of KB75).  The PCR primers were designed so that this fragment would be flanked by two 
Xhol restriction sites, thus aUowing it to be easily ligated into the unique Xhol site of pKB75. This ligation resulted in a DNA fragment 
encoding a new version of KB75 where the domain extending from Thr-306 to Met-335 is deleted, therefore resulting in a fusion of Glu-305 
to Arg-336. To prevent translation from proceeding beyond the BglII site,  which would result in the production of an aberrant peptide, 
a STOP codon was included in the 3' primer of the PCR. (B) This scheme shows the regions of APP-695 encoded by the plasmids pKB75 
and pKB75& None of them contains the signal sequence, or the O/A4, or the transmembraue or cytoplasmic domains. The KPI domain 
is shown only to indicate its insertion point in APP-751,  but it is not present either in KB75 or KB75& (C) Identification of APP-related 
proteins in bacteria. SNiff fractions (25 ttg'of total protein in each lane) from bacteria carrying either pKB75 or pKB75# were prepared 
as described (Roch et al.,  1992), separated by SDS PAGE,  and analyzed by immunoblotting with anti-GID antibody, diluted  1:2,000 (a 
rabbit polyclonal antibody against the peptide 175-186 of APP; see Saitoh et al., 1989).  As expected, the form of APP encoded by pKB756 
was slightly smaller than that encoded by pKB75. 
size-exclusion  HPLC.  The  apparent  homogeneity  was 
judged  by  Coomassie  blue  staining  of the  gel  after  elec- 
trophoresis in the presence of SDS (data not shown).  When 
KB756 thus verified was tested on A-1 cell growth assay, we 
could see no activity (Fig. 5), in agreement with the sugges- 
tion  that  the  sequence  Thr-306  to  Met-335  which  was 
deleted  in KB756 was essential  for the activity. 
The purification of KB75/KB75~ from bacterial lysate in- 
volved the use of heparin-agarose column, in which we unex- 
pectedly noticed that the ionic strength of NaC1 required for 
the elution of KB75~ was constantly lower than that required 
for the elution of KB75 (Fig.  6), suggesting that the deleted 
sequence in KB756 contained a  heparin-binding  domain of 
KB75,  or  alternatively,  the  deletion  caused  a  significant 
change in the structure of the molecule resulting in a reduced 
Figure 5. KB756 lacked growth-promoting activity on A-1 cells. The 
growth assay on A-1 cells was performed using increasing concen- 
trations of KW/5 or KB75& See legend to Fig.  1 for details. Each 
point represents the mean ±  SEM of at least four determinations, 
each done in triplicate. *, p <  0.05, significantly different from the 
basal increase (differences were assessed by ANOVA followed by 
the Dunnett's test). 
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KB75~, KW/5 and  synthetic 
peptides from heparin-agarose 
column. SNI/I fractions from 
bacteria carrying either pKB75 
or pKB758 were prepared as 
described (Roch et al., 1992). 
30 mg of total protein of each 
fraction were then mixed and 
loaded onto a heparin-agarose 
column, in PBS at 4°C (total 
amount of protein loaded, 60 
mg).  The  flow-rate was  40 
ml/h.  Elution  from  the  col- 
uinn was monitored by absor- 
bance at 280 nm (not shown). 
After washing  with PBS, a lin- 
ear gradient of NaCI (0.15-1.0 
M) was run through the column. Fractions of 1 ml were collected. Aliquots of 25 #1 of each fraction were then analyzed by SDS PAGE 
and immunoblotting with the anti-GID antibody. Only the fractions containing APP-related proteins are shown on this figure and aligned 
with the profile of NaCI concentration. The elution profiles of KB75 and KB75~  were different. Consistent with our previous finding (Roch 
et al., 1992), KW/5 was eluted at about 0.8 M NaCI. In contrast, KB756 was eluted at 0.45 M, showing thus a reduced affinity for heparin. 
In another set of experiments, the synthetic peptide corresponding to the deleted sequence in KB75~ (40-met, open circles; 17-mer, closed 
circles), each 10 #g, was loaded to the same column and eluted in the same way. In this case, absorbance at 215 mn was monitored. As 
shown, both of the peptides were recovered in the flow-through  fractions (PBS; 0.15 M NaCI), indicating the poor affinity of these peptides 
to heparin. 
heparin-binding affinity.  To see which was the case, we ap- 
plied the synthetic peptides corresponding to the deleted se- 
quence (i.e., 40-mer and 17-mer) to the same heparin affinity 
column but found no heparin-binding capacity for the pep- 
tides (Fig. 6). Thus, although the deleted sequence in KB75~ 
might contribute to the heparin-binding capacity of sAPP- 
695 in an unknown way, the biological activity of the active 
domain included in the deleted sequence apparently is not 
due to heparin binding. 
Discussion 
We have mapped the growth-promoting activity of sAPP-695 
to a domain of  five amino acids RERMS (APP328-332) (Fig. 
1).  The concentration of peptide needed for a  significant 
effect, however, was 'M0-fold higher for RERMS than for ei- 
ther the 11-mer or 17-mer, suggesting that the amino acid se- 
quence in the vicinity was necessary for the full activity. The 
reverse-sequence 17-mer had no activity (Fig.  1 C), further 
indicating the sequence specificity of the activity. We also 
found that  the four-amino-acid peptide  RMSQ  (APP330- 
333),  which  partially  overlaps  the  COOH-terminal  side 
of the active sequence RERMS could antagonize the activity 
of either the 17-mer or KI~5 (Fig. 3). The lack of activity 
of KB755 in the A-1  cell bioassay can be explained if the 
deleted sequence in KB75~ (APP306-335) contains the only 
site capable of growth stimulation, or if a  conformational 
modification results in a loss of activity. A change in confor- 
mation may be induced by the deletion of APP306-335 in 
KB756 because we observed a reduced affinity for heparin 
of KB75~ as compared to KB75,  in spite of the absence of 
heparin-binding activity in the 40-mer and 17-mer peptides. 
However, the activity of KB75 could be totally antagonized 
by the tetramer RMSQ, indicating that the RERMS domain 
is uniquely responsible for the growth promotion, and that 
no other site in KB75 could stimulate the growth of fibro- 
blasts. 
The RERMS motif and its NH~-terminal side amino acid 
sequence have some interesting characteristics. First, the se- 
quence RERMS is unique to APP; we found no match in the 
peptide sequences so far registered in GenBank. Second, it 
is within one of the evolutionarily highly conserved regions 
of APP (Rosen et al.,  1989). Exactly the same sequence as 
40-met is found in mammalian APPs (rat, mouse, and mon- 
key). In the Drosophila "APP-like" molecule, there is a se- 
quence REKVT (aa 423-427; Rosen et al., 1989); the polar- 
ity of the side chains of the corresponding residues is very 
similar to RERMS (K and R have basic, V and M have non- 
polar, and T and S have uncharged polar side chains, respec- 
tively). The uniqueness and the high evolutionary conserva- 
tion both suggest the fundamental role of the sequence in the 
physiological function(s) of sAPP. 
We could thus identify a unique region of APP which was 
active on our A-1 cell bioassay. The biochemical mechanism 
of the activity, however, is still unknown. In previous reports 
(Saitoh et al.,  1989;  Roch et al.,  1992), we proposed two 
possible mechanisms. The first is the possible effect of APP 
on A-1 cell adhesion. Many reports have suggested the role 
of APP in cell adhesion (Shubert et al., 1989a; Breen et al., 
1991;  Chen  and  Yankner,  1991). APP binds  to heparan- 
sulfate proteoglycan (Narindrasorasak et al.,  1991),  which 
is supposed to be involved in cell-extracellular matrix inter- 
action. Our preliminary experiments indicated a significant 
reduction in the adhesiveness of A1  cells compared to that 
of the parent cells, AG2804 (data not shown). Because we 
have not been able, so far, to increase the adhesiveness of  A-1 
cells  using  soluble  or  immobilized  KB75,  more  work  is 
needed for a better understanding of the involvement of APP 
in cell adhesion. It is possible that co- and post-translational 
processing, such as glycosylation, or transmembrane config- 
The Journal of Cell Biology, Volume  121, 1993  884 uration, in contrast to secreted form, are required for the cell 
adhesive property of APP.  The second possible mechanism 
we proposed is the effect(s) of sAPP on the intracellular sig- 
nal  transduction  machineries  through  an  interaction  with 
cell-surface receptor molecule(s).  The sequence specificity 
of the activity and the antagonistic actions of partially  over- 
lapping, inactive peptides are compatible with this notion, 
although direct evidence for the presence of a cell-surface 
recognition molecule for sAPP is still lacking. 
APP is one of the hepafin-binding proteins (Schubert et 
al., 1989b), the reason why we used heparin-agarose column 
to purify it from the bacterial lysate (Roch et al.,  1992).  In 
the course of purification of KB75  and KB758  expressed in 
bacteria,  we noticed that the binding affinity  of KI~58  to 
heparin-agarose column was lower than that of KB75  (Fig. 
6). The lack of the heparin-binding capacity of biologically 
active,  synthetic peptides corresponding to the deleted se- 
quence in KB758  (Fig. 6), however, excluded the active in- 
volvement of the binding to heparin or heparinlike mole- 
cules, which are presumably present in the assay media or 
on the cell surface, in the growth-promoting activity.  Further 
evidence for the absence of contribution of heparin-binding 
capacity to the activity is that the inclusion of either heparin 
or heparan  sulfate  in the assay media (both  at  100 #g/rnl) 
failed to inhibit the effect of either 17-mer or KB75 (data not 
shown).  A  potential  heparin-binding  site  on  sAPP-695 
predicted from the consensus sequence (Cardin  and Wein- 
traub,  1989) is not on the active domain but on APP98-104 
(Narindrasorasak et al., 1991).  Thus, although the sequence 
APP306-335 may contribute to the heparin-binding capacity 
of sAPP-695 in its native form of the molecule, the growth- 
promoting activity of the domain in itself had little to do with 
the heparin-binding capacity. 
In summary,  using our bioassay on A-1 cells, we showed 
that the site of sAPP-695 responsible for the growth stimula- 
tion is represented by the five-amino-acid sequence RERMS 
(APP328-332),  and that this site is unique in the APP mole- 
cule. The biochemical basis for the activity is still unknown. 
Recent studies in our laboratory have revealed that the bio- 
logical activity of this domain of sAPP is not confined to this 
particular cell line; the addition of synthetic peptides corre- 
sponding  to  this  domain  to  the  culture  media  caused 
significant morphological and biochemical changes in either 
neuroblastoma cells from rat brain or primary cortical neu- 
rons from newborn rat (manuscript in preparation).  Thus, 
sAPP  seems  to  be  involved  in  the  regulation  of cellular 
homeostasis  in various cell lines.  In a previous  study,  we 
found that cultured  fibroblasts  from the skin of AD patients 
produced a smaller amount of APPs compared to fibroblasts 
from normal individuals  (Utda  et al.,  1989).  There have 
been several reports describing the reduction of the relative 
proportion of APP-695 to the KPI-containing forms of APP 
in postmortem brains from AD patients (Tanaka et al., 1988; 
Johnson et al., 1990; Neve et al., 1990). More recently, Van 
Nostrand  et al.  (1992)  reported a  significant reduction of 
sAPP in the cerebrospinal fluid of live AD patients.  These 
findings raised a possibility that, in addition to the COOH- 
terminal ~/A4 portion of APP which is involved in amyloido- 
genesis, the secreted portion of APP is also involved in the 
pathogenesis of AD.  We expect that the biologically active 
peptides and their antagonists  described in the present study 
will be useful tools to study the possible involvement of the 
biological  activity  of  sAPP-695  in  various  experimental 
model systems for the pathogenesis of AD. 
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